Krystal Biotech, Inc. (KRYS) AI Stock Analysis

Krystal Biotech, Inc. is a biotechnology company pioneering redosable gene therapy for severe rare diseases across the United States. Its lead candidate is beremagene geperpavec (B-VEC), undergoing Phase III trials for dystrophic epidermolysis bullosa. The company is also advancing KB105 in Phase I/II trials for autosomal recessive congenital ichthyosis and KB301 in Phase I/II stages for skin aging and related conditions. Its pipeline extends to preclinical candidates including KB407 for cystic fibrosis and KB104 for netherton syndrome, alongside discovery-stage programs KB5xx and KB3xx targeting chronic and aesthetic dermatological conditions. Founded in 2015 and based in Pittsburgh, Pennsylvania, the firm employs 295 people.

Krystal Biotech expanded annual revenue from $1.0M in FY2018 to $50.7M in FY2023, $290.5M in FY2024, and $389.1M in FY2025, representing a 3-year revenue CAGR of 623.6%. Gross margin reached 92.6% in FY2025, while operating margin expanded to 41.5% from 22.6% in FY2024. FY2025 net income reached $204.8M, or $6.85 per share, up from $89.2M in FY2024. Trailing twelve month revenue stood at $440.5M with a profit margin of 54.8% and operating margin of 49.0%. For the latest quarter ended June 30, 2026, revenue increased 24.1% year-over-year, while quarterly earnings grew 38.8%.

As of June 30, 2026, Krystal Biotech held $845.6M in cash and short-term investments and $8.9M in total debt, resulting in net cash of $836.8M. Total assets were $1.50B against shareholders' equity of $1.36B, supporting a current ratio of 8.32 and a debt-to-equity ratio of 0.01. Operating cash flow grew to $200.9M in FY2025, while capital expenditures totaled $12.0M, generating $188.9M in free cash flow. Over the past five years, the company's share count increased 38.1%.

At a share price of $316.58, Krystal Biotech has a market capitalization of $9.37B and an enterprise value of $9.28B. The stock trades at a trailing P/E of 39.7x, a forward P/E of 46.9x, and an EV/EBITDA of 45.4x, which compare to the median of its US-listed Healthcare peers of 24.6x, 17.3x, and 12.0x, respectively. Over the trailing 12 months, the stock returned 68.1% compared to a 16.8% return for SPY, and its 5-year return reached 549.8% versus 83.0% for SPY.

Wall Street coverage includes 10 Strong Buy, 1 Buy, and 1 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $395.44, representing a 24.9% premium over the last close of $316.58. Analysts forecast full-year FY2026 revenue of $498.2M and EPS of $7.62, followed by FY2027 estimates of $638.3M in revenue and $9.05 in EPS based on 11 analysts. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Krystal Biotech, Inc. (KRYS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KRYS income statement, KRYS balance sheet, KRYS key metrics, KRYS analyst forecast, KRYS chart. See the KRYS stock overview for the latest quote and news.